Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etofibrate SCHEMBL8168409 | 1.00 | L3MBTL1 (0.55) | L3MBTL1KMT2ALMNAALDH1A1MEN1 | |
| Etofibrate SCHEMBL3122 | 1.00 | L3MBTL1 (0.55) | L3MBTL1KMT2ALMNAALDH1A1MEN1 | |
| Etofibrate SCHEMBL1649349 | 0.99 | L3MBTL1 (0.54) | L3MBTL1KMT2ALMNAALDH1A1MEN1 | |
| Ronifibrate SCHEMBL48852 | 0.96 | L3MBTL1 (0.59) | L3MBTL1KMT2ALMNAALDH1A1MEN1 | |
| Simfibrate SCHEMBL5808862 | 0.96 | L3MBTL1 (0.59) | L3MBTL1KMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL10973734 | 0.92 | L3MBTL1 (0.55) | L3MBTL1KMT2ALMNAALDH1A1MEN1 | |
| Picafibrate SCHEMBL2109083 | 0.85 | SMN1; SMN2 (0.65) | KMT2ALMNAALDH1A1MEN1USP2 | |
| Binifibrate SCHEMBL49116 | 0.85 | KMT2A (0.51) | L3MBTL1KMT2ALMNAALDH1A1MEN1 | |
| Binifibrate SCHEMBL29388376 | 0.85 | KMT2A (0.51) | L3MBTL1KMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL2615470 | 0.84 | L3MBTL1 (0.59) | L3MBTL1KMT2ALMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115397412-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-3674298-B9 | SUBSTITUTED INDAZOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS | Bayer Pharma AG (DE) | 2024-06-19 | — | — | EP | disclosed |
| EP-3674298-B1 | SUBSTITUTED INDAZOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS | Bayer Pharma AG (DE) | 2024-01-10 | — | — | EP | disclosed |
| EP-4301728-A1 | ARYLSULFOXAMIDES AS OREXIN RECEPTOR AGONISTS | Research Triangle Institute (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4260909-A2 | SUBSTITUTED INDAZOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE IN THE PREPARATION OF DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2023-10-18 | — | — | EP | disclosed |
| CN-116568802-A | In vitro method for preparing mature red blood cells | 西湖生物医药科技(上海)有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4104838-A1 | Use of DPP IV inhibitors | Boehringer Ingelheim International GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022187231-A1 | ARYLSULFOXAMIDES AS OREXIN RECEPTOR AGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-2397142-B1 | Use of DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2022-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | L3MBTL1 4635/4885KMT2A 3704/4885LMNA 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.